Polycythemia vera ppts and latest articles

Myeloproliferative Disorders
Alice Ma, M.D.
http://www.med.unc.edu/medicine/web/6.11.07%20Myeloproloferative%20Ma.ppt

Polycythemia Vera
http://www.med.unc.edu/medicine/web/2.28.08%20PVC%20Gibbs.ppt

Diagnostic  Approach to Myeloproliferative Neoplasms
Stephen  Oh, M.D, Ph.D.
http://hematology.wustl.edu/conferences/presentations/Oh20110819.ppt

Chronic  Myeloid Leukemia and  other Myeloproliferative  Neoplasms (MPNs)
by Dale Bixby,  M.D., Ph.D
http://open.umich.edu/sites/default/files/2580/011309.DBixby.MyeloproliferativeDisorders.ppt

Hypercoagulable  States: Polycythemia Vera
by Chris  Caulfield
https://medicine.med.unc.edu/education/internal-medicine-residency-program/files/ppt/10.20.09%20Caulfield%20Polycythemia%20vera.ppt

Neoplastic  Disorders of The Bone  Marrow
http://instructional1.calstatela.edu/nmcquee/Micro410/Lecture%2013%20-%20Neoplastic%20disorders%20of%20the%20bone%20marrow.ppt

Polycythemia Vera
http://www.medicine.wisc.edu/~williams/polycythemia.ppt

Latest 20 articles

1. Erectile dysfunction in polycythemia vera.
2. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response and resistance/intolerance to hydroxyurea in polycythemia vera.
3. Assessment of left ventricular myocardial performance by tissue Doppler echocardiography in patients with polycythemia vera.
4. Critical requirement for Stat5 in a mouse model of polycythemia vera.
5. Cutaneous effects after prolongaded use of hydroxyurea in Polycythemia Vera.
6. CYP1AI, glutathione S-transferase gene polymorphisms and risk of Polycythemia vera.
7. Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.
8. Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera.
9. Evaluation of hemostatic balance in blood from patients with polycythemia vera by means of thromboelastography: The effect of isovolemic erythrocytapheresis.
10. How to manage polycythemia vera.
11. Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children.
12. Persistent neutrophilia progressing to polycythemia vera.
13. Polycythemia vera with pancytopenia and red cell fragmentation.
14. Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
15. The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera.
16. Torque teno virus 10 isolated by genome amplification techniques from a patient with concomitant chronic lymphocytic leukemia and polycythemia vera.
17. Transient spinal cord ischemia as presenting manifestation of polycythemia vera.
18. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.
19. Treatment of polycythemia vera with imatinib mesylate.
20. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.